Best Antidepressant for Patients Over 60 Years Old
For patients over 60 years old with depression, escitalopram, citalopram, or sertraline should be the first-line antidepressant choices, with escitalopram demonstrating the highest acceptability in real-world use. 1, 2
Primary Recommendations
The preferred antidepressants for older adults are:
First-tier options:
- Escitalopram - Highest acceptability in both younger and older patients in a large French nationwide cohort study 2
- Citalopram - Favorable adverse effect profile, though maximum dose is limited to 20 mg/day in patients >60 years due to QT prolongation risk 1, 3
- Sertraline - Consistently achieves 50% or higher remission rates and has the lowest potential for drug interactions among SSRIs 1, 4, 5
Second-tier options:
- Mirtazapine - Ranks 2nd in acceptability specifically in older patients (versus 15th in younger patients), useful when sedation and appetite stimulation are desired 1, 2
- Bupropion - Activating properties, lowest hospitalization risk in older veterans, avoid in agitated patients 1, 6
- Venlafaxine - Acceptable option but requires dose adjustment in renal impairment 1, 7
Medications to Avoid
Explicitly avoid in older adults:
- Paroxetine - Excessive anticholinergic effects 1
- Fluoxetine - Greater risk of agitation and overstimulation 1
- Tertiary-amine TCAs (amitriptyline, imipramine) - Significant anticholinergic effects, orthostatic hypotension, cardiac conduction issues; considered potentially inappropriate by Beers Criteria 1, 8
Dosing Principles
Start at approximately 50% of standard adult doses and titrate slowly 1. Specific starting doses:
- Escitalopram: 5-10 mg daily
- Citalopram: 10 mg daily (maximum 20 mg in patients >60 years) 3
- Sertraline: 25-50 mg daily
- Mirtazapine: 7.5 mg at bedtime 9
Evidence Quality and Nuances
The 2015 American Family Physician guidelines 1 provide the strongest consensus-based recommendations, explicitly stating preferred agents based on favorable adverse effect profiles. These guidelines note that SSRIs and TCAs show no difference in effectiveness, but TCAs have significantly higher withdrawal rates due to adverse reactions 1.
The most recent high-quality evidence comes from a 2026 French nationwide cohort study of 83,673 patients ≥65 years 2, which used real-world filled prescription sequences to measure "acceptability" (combination of efficacy and tolerability). This study found escitalopram ranked first regardless of age, but notably, mirtazapine and mianserin showed substantially better acceptability in older versus younger patients - a clinically important age-specific finding.
A 2025 VA database study of 142,138 older veterans 6 found duloxetine had the lowest risks of treatment change and augmentation, while mirtazapine had the highest risks of all adverse outcomes including hospitalization. However, this contradicts the French study's findings on mirtazapine acceptability, likely reflecting different patient populations and outcome measures.
Special Considerations
Renal impairment: Venlafaxine requires dose adjustment even in mild renal impairment (GFR monitoring recommended), while mirtazapine, sertraline, and escitalopram appear well-suited for patients with stage 2-3 renal impairment 7.
Cardiac concerns: Citalopram and escitalopram have FDA-mandated dose restrictions due to QT prolongation risk 3. TCAs can cause AV block and have been associated with increased cardiac arrest risk (OR 1.69) 3.
Polypharmacy: Sertraline has the lowest potential for cytochrome P450 drug interactions among SSRIs, making it advantageous in older adults on multiple medications 5, 10.
Treatment duration: Continue for at least 4-12 months after first episode; patients with recurrent depression (≥3 episodes) benefit from prolonged treatment beyond 1 year 1.
Common Pitfalls
- Underdosing: While starting low is appropriate, failure to titrate to therapeutic doses results in inadequate trials
- Premature discontinuation: Adequate trial requires 4-6 weeks at therapeutic dose 1
- Ignoring anticholinergic burden: Combining multiple anticholinergic medications (including TCAs) increases fall risk, cognitive impairment, and functional decline 11
- Not monitoring for hyponatremia: All SSRIs can cause SIADH, particularly problematic in older adults 8